GlobeNewswire·Dec 10, 2025, 12:14 AM ET

Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Denali Therapeutics Inc. priced an underwritten public offering of 9,142,857 shares of common stock at $17.50 per share.
The company also issued 2,285,714 pre-funded warrants at $17.49 per warrant to certain investors in lieu of common stock.
Denali Therapeutics expects to receive approximately $200 million in total gross proceeds before deducting underwriting discounts, commissions, & offering expenses.
Underwriters were granted a 30-day option to purchase up to an additional 1,714,285 shares of common stock.
The offering is scheduled to close on or about December 11, 2025, subject to customary closing conditions.
Goldman Sachs, J.P. Morgan, Morgan Stanley, & Jefferies are acting as joint book-running managers, while H.C. Wainwright & B. Riley Securities serve as co-managers.
The offering is registered on Form S-3, which became effective on February 27, 2025, with a preliminary prospectus supplement filed on December 9, 2025.
Final prospectus supplements & accompanying documents will be filed with the SEC & are available free of charge at www.sec.gov.
Denali Therapeutics is a biotechnology company utilizing its proprietary TransportVehicle™ platform to develop biotherapeutics for neurodegenerative & lysosomal storage diseases.